Results 51 to 60 of about 309 (104)

Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models. [PDF]

J Pharmacokinet Pharmacodyn, 2015
Danhof M.
europepmc   +1 more source

Advancements in the design and development of pyrazoline-based antimycobacterial agents: an update and future perspectives. [PDF]

RSC Adv
Rakshit G, Chakraborty S, Bhakta S, Jayaprakash V.   +3 more
europepmc   +1 more source

Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes. [PDF]

Hepatology, 2009
Dong B, Qatanani M, Moore DD.
europepmc   +1 more source

Pharmacotherapy for hyperuricemia in hypertensive patients. [PDF]

Cochrane Database Syst Rev, 2017
Gois PHF, Souza ERM.
europepmc   +1 more source

Design, synthesis and biological evaluation of benzoxazolinone-containing 1,3,4-thiadiazoles as TNF-α inhibitors. [PDF]

Heliyon, 2019
Haider S, Alam MS, Hamid H, Dhulap A, Kumar D.   +4 more
europepmc   +1 more source

Hyperuricemia and Hypertension: Links and Risks. [PDF]

Integr Blood Press Control, 2019
Stewart DJ, Langlois V, Noone D.
europepmc   +1 more source

Common and Uncommon Mouse Models of Growth Hormone Deficiency.

Endocr Rev
List EO, Basu R, Berryman DE, Duran-Ortiz S, Martos-Moreno GÁ, Kopchick JJ.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Zoxazolamine — A Potent Uricosuric Agent

New England Journal of Medicine, 1958
ZOXAZOLAMINE¶ has been widely used during the past two years for the purpose of decreasing spasm of skeletal muscle, presumably via a depressant effect upon polysynaptic pathways in the central nervous system. Occasional side effects, such as drowsiness, lightheadedness, dizziness, abdominal discomfort, vomiting, headache and transient blotching of the
E B, Reed, T V, Feichtmeir, F M, Willett
openaire   +2 more sources

ZOXAZOLAMINE (FLEXIN) IN RHEUMATIC DISEASES

Journal of the American Medical Association, 1956
• Zoxazolamine prevents or relieves spasm in voluntary muscles by depressing the central nervous pathways involved. It was administered by mouth to 100 rheumatic patients in whom the muscular stiffness and soreness made it impossible to carry out the necessary program of exercise. Relief of the stiffness and aching was often complete within 30 minutes
R T, SMITH, K M, KRON, W P, PEAK, I F, HERMANN   +3 more
openaire   +2 more sources